NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other CancersWen Zhou, Fenghuang Zhan, Ye Yang et al.|Cancer Cell|2013Cited by 302
Identification and Characterization of Tumor-Initiating Cells in Multiple MyelomaMinjie Gao, Fenghuang Zhan, Hua Bai et al.|JNCI Journal of the National Cancer Institute|2019Cited by 47
Alterations of Gut Microbiome Accelerate Multiple Myeloma Progression By Increasing the Relative Abundances of Nitrogen Recycling BacteriaXingxing Jian, Wen Zhou, Juanjuan Xiang et al.|Blood|2019Cited by 11
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapyYanjuan He, Fangping Chen, Duanfeng Jiang et al.|Journal of Cancer|2021Cited by 10
Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) StudiesMaurizio Zangari, Fenghuang Zhan, Tamara Berno et al.|Blood|2012Cited by 2